Skip to main content
Smart Investors Daily
KI

NYSE · KIO

KKR Income Opportunities Fund

Financial Services · Asset Management - Income

$10.38

Up+$0.21 (+2.06%)

Updated Oct 7, 2026, 11:09 AM

SID Score

3.2/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
479.82M
P/E ratio
64.6
Dividend yield
16.45%
52-week range
$10.17 – $11.46
Volume
297.95K
Avg. volume
339.62K

Price performance · KIO

KIO price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Oct 6, 2026

KIO closed at $10.38 after 21 trading sessions, down 5.72% for the selected period.

Last close
$10.38
Period change
-5.72%
Period low
$10.17
Period high
$11.01
Daily close
View OHLC price history
KIO OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 6, 2026$10.23$10.38$10.1801$10.38297.95K
Oct 5, 2026$10.37$10.37$10.17$10.17255K
Oct 2, 2026$10.28$10.415$10.28$10.35276.63K
Oct 1, 2026$10.27$10.301$10.165$10.28256.24K
Sep 30, 2026$10.38$10.3999$10.29$10.30294.97K
Sep 29, 2026$10.26$10.33$10.23$10.33227.21K
Sep 28, 2026$10.40$10.449$10.22$10.22316.62K
Sep 25, 2026$10.34$10.445$10.3108$10.44201.47K
Sep 24, 2026$10.44$10.44$10.30$10.30290.21K
Sep 23, 2026$10.57$10.60$10.42$10.44259.52K
Sep 22, 2026$10.61$10.645$10.58$10.60143.18K
Sep 21, 2026$10.67$10.68$10.56$10.63144.4K
Sep 18, 2026$10.72$10.74$10.61$10.61208.59K
Sep 17, 2026$10.70$10.74$10.67$10.73163.07K
Sep 16, 2026$10.69$10.75$10.68$10.68156.3K
Sep 15, 2026$10.85$10.85$10.68$10.72345.46K
Sep 14, 2026$10.91$10.93$10.80$10.85209.33K
Sep 11, 2026$10.89$10.98$10.89$10.95425.01K
Sep 10, 2026$10.95$10.97$10.8806$10.95399K
Sep 9, 2026$11.01$11.02$10.97$10.97104.06K
Sep 8, 2026$11.04$11.06$10.985$11.01130.4K

Latest KIO news

The latest Smart Investors Daily articles mentioning KIO.

KIO research

Overview

Company profile and research snapshot.

Company profile

KKR Income Opportunities Fund operates as a closed-end registered management investment company. It seeks to generate a high level of current income, with a secondary objective of capital appreciation. The company invests in the portfolio of loans and fixed-income instruments of U.S. and non-U.S. issuers. The company will invest at least 80% of its Managed Assets in loans and fixed-income instruments or other instruments, including derivative instruments, with similar economic characteristics under normal market conditions.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 22, 2026

South African Steel Stocks Facing A Tariff Reset Investors Should Watch

South Africa is quietly redrawing the rules of its steel market, with fresh tariffs, import controls and anti dumping duties creating a very different earning backdrop for local producers. That reshuffle can shift pricing power, squeeze some users and open space for others. This article explains how those policy moves intersect with three South African steel stocks exposed to the news, and why their changing risk profile matters for your portfolio decisions. The stocks in the list below are...

Yahoo · Sep 10, 2026

KKR Income Opportunities Fund Declares Monthly Distributions of $0.1215 Per Share

NEW YORK, September 10, 2026--KKR Income Opportunities Fund (the "Fund") (NYSE: KIO) today announced its monthly distributions of $0.1215 per common share, payable on the dates below. Based on the Fund’s current share price of $10.97 per share (as of market close on September 9, 2026), the distributions represent an annualized distribution rate of 13.29% (calculated by annualizing the distribution amount and dividing it by the current price).

newsfilecorp.com · Dec 1, 2025

Kiora Pharmaceuticals Granted U.S. Patent Covering Additional Formulations for the KIO-100 Family of Anti-Inflammatory Compounds

Encinitas, California--(Newsfile Corp. - December 1, 2025) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) today announced that the U.S. Patent and Trademark Office issued a new patent (US-12,472,263) on additional and novel formulations of the KIO-100 family of compounds, This patent allows for additional delivery options, expanding the potential therapeutic utility of the active pharmaceutical ingredient (API) in KIO-104. This newly issued patent specifically covers a novel formulation of the API in KIO-104.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.